JW (Cayman) Therapeutics Co. Ltd
HKEX:2126.HK
1.42 (HKD) • At close November 12, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | JW (Cayman) Therapeutics Co. Ltd |
Symbool | 2126.HK |
Munteenheid | HKD |
Prijs | 1.42 |
Beurswaarde | 574,534,685 |
Dividendpercentage | 0% |
52-weken bereik | 1.19 - 3.49 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Yiping Li M.D. |
Website | https://www.jwtherapeutics.com |
An error occurred while fetching data.
Over JW (Cayman) Therapeutics Co. Ltd
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (HKD)
Cijfers zijn in miljoenen (HKD)